Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Thalidomide does not interact with P-glycoprotein.

Christian Zimmermann¹, Heike Gutmann, Juergen Drewe

¹Department of Clinical Pharmacology and Toxicology Petersgraben, University Hospital Basel and Department of Pharmaceutical Sciences, Petersgraben 4, CH-4031, Basel, Switzerland.

Cancer Chemotherapy and Pharmacology

|September 2, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

In Vivo Characterization of the <i>dia</i> Biosynthetic Gene Cluster Reveals Diaporthinic Acid as Its Main Product.

Journal of fungi (Basel, Switzerland)·2026

Same author

Impact of allyl-isothiocyanate and high sucrose diet on antimicrobial peptide expression and survival in <i>Drosophila melanogaster</i>.

Frontiers in immunology·2026

Same author

Exploring the use of hydrophilic ionic liquids for the lysis of fungal structures.

Journal of microbiological methods·2026

Same author

Intensified upstream processing by a phosphate-regulated, auto-inducible expression system in E. coli W3110 for recombinant Fab production.

BMC microbiology·2026

Same author

Phenogenomics reveals the ecology and evolution of Trichoderma fungi for sustainable agriculture.

Nature microbiology·2026

Same author

Life on the rocks: unexpected enzyme activity of the extremophilic black fungus <i>Knufia chersonesos</i>.

Frontiers in bioengineering and biotechnology·2026

Same journal

Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome.

Cancer chemotherapy and pharmacology·2026

Same journal

CDK4/6 inhibitor-statin interaction and rhabdomyolysis in breast cancer treatment: a case-based systematic review.

Cancer chemotherapy and pharmacology·2026

Same journal

ALK rearrangements and resistance mutations in non-small cell lung cancer: molecular mechanisms and therapeutic implications.

Cancer chemotherapy and pharmacology·2026

Same journal

Central nervous system penetration of imatinib in acute lymphoblastic leukemia: Pharmacokinetic analysis and clinical implications.

Cancer chemotherapy and pharmacology·2026

Same journal

Severe Methotrexate toxicity after ectopic pregnancy: a case report managed with continuous renal replacement therapy.

Cancer chemotherapy and pharmacology·2026

Same journal

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026

See all related articles

Thalidomide does not interact with P-glycoprotein (P-gp), a transporter involved in drug-drug interactions. This suggests thalidomide is unlikely to cause P-gp related side effects when used with other medications.

Area of Science:

Pharmacology
Drug Metabolism
Drug Interactions

Background:

Thalidomide exhibits anti-inflammatory, immunomodulatory, and anti-angiogenic properties, leading to increased clinical interest.
Thalidomide is frequently used as an adjunct therapy in clinical trials.
Understanding potential drug-drug interactions is crucial for clinicians, especially concerning P-glycoprotein (P-gp), a key drug efflux transporter.

Purpose of the Study:

To investigate thalidomide's potential to induce or inhibit P-glycoprotein (P-gp).
To assess thalidomide's role in P-gp mediated drug-drug interactions.

Main Methods:

Real-time RT-PCR was used to determine P-gp induction in LS180 cells after thalidomide incubation.
Rhodamine 123 uptake was measured in CCRF-CEM/MDR1 cells to assess P-gp substrate transport in the presence of thalidomide.

Related Experiment Videos

Caco-2 cell monolayers were used to evaluate dose-dependent and bi-directional transport of thalidomide.

Main Results:

Thalidomide did not induce P-gp expression in LS180 cells.
Co-incubation with thalidomide did not affect rhodamine 123 uptake in P-gp over-expressing cells.
Thalidomide exhibited linear, bi-directional transport across Caco-2 cell monolayers with no enantiomeric differences observed.

Conclusions:

Thalidomide is neither a substrate, inhibitor, nor inducer of P-glycoprotein (P-gp).
P-gp-related drug-drug interactions involving thalidomide are unlikely.